This inventor holds 31 USPTO granted patents and 3 published patent applications and 18 EPO patents. Top assignees: Daiichi Sankyo Company, Limited, Nissan Motor Company Limited, Ebara Corporation. Active years: 1982-2025.
Location History:
- Higashikurume, JP (1982)
- Zushi, JP (2015 - 2020)
- Kanagawa, JP (2020)
- Tokyo, JP (1984 - 2023)
Company Filing History:
12 out of 460 
12 out of 13,420 
3 out of 2,573 
Years Active: 1982-2025
Areas of Expertise:
Title: The Innovative Journey of Masao Yoshida: Pioneering Antibody-Drug Conjugates
Introduction: Masao Yoshida, an accomplished inventor based in Tokyo, Japan, is renowned for his significant contributions to the field of biotechnology. With an impressive portfolio of 18 patents, Yoshida has dedicated his career to developing innovative therapies that enhance cancer treatment strategies. His work primarily focuses on antibody-drug conjugates, which represent a novel approach in oncology.
Latest Patents: Among Yoshida's latest patents are two notable advancements in antibody-drug conjugates. The first patent describes an antitumor drug that boasts excellent efficacy and safety. This invention articulates a Linker structure (-L-L-L-NH—(CH)n-L-L-L-) that connects an anti-tumor compound to an antibody. The innovative design aims to maximize therapeutic impact while minimizing side effects. The second patent elaborates on a method for treating cancer that uses an anti-HER2 antibody-drug conjugate, showcasing a similar structure. This patent emphasizes the conjugation of an antitumor compound to an anti-HER2 antibody, further advancing the landscape of targeted cancer therapies.
Career Highlights: Over his illustrious career, Masao Yoshida has collaborated with well-known companies such as Daiichi Sankyo Company, Limited and Ebara Corporation. His experiences in these reputable organizations have played a pivotal role in shaping his innovative approaches to drug development.
Collaborations: Collaboration has been a cornerstone of Yoshida's success. He has worked closely with talented individuals, including Hiroyuki Naito and Takashi Nakada, who have contributed to various projects and research endeavors, enhancing the outcomes of his inventions.
Conclusion: Masao Yoshida's innovative spirit and scientific contributions are transforming cancer treatment through the development of antibody-drug conjugates. His extensive patent portfolio reflects his dedication to improving patient outcomes and driving advancements in the biotechnology field. As he continues to explore new horizons, Yoshida's work will undoubtedly leave a lasting impact on the world of medical science.